TMO EPM / Hemato H9J
By TMO EPM / Hemato H9J
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by TMO EPM / Hemato H9J
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 75
Description
Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA
| Episode | Date |
|---|---|
|
75 - Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
|
Jun 05, 2026 |
|
74 - Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
|
May 27, 2026 |
|
73 - Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
|
May 23, 2026 |
|
72 - Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma
|
May 20, 2026 |
|
71 - Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
|
May 04, 2026 |
|
70 - Intermediate-Dose Cytarabine as Postinduction AML Therapy
|
Apr 08, 2026 |
|
69 - Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
|
Mar 11, 2026 |
|
68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Jan 11, 2026 |
|
67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
|
Jan 07, 2026 |
|
66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
|
Dec 30, 2025 |
|
65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
|
Nov 05, 2025 |
|
64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
|
Nov 02, 2025 |
|
63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
|
Sep 01, 2025 |
|
62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation
|
Aug 10, 2025 |
|
61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
|
Aug 04, 2025 |
|
60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
|
Jul 27, 2025 |
|
59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation
|
Jul 23, 2025 |
|
58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study
|
Jul 13, 2025 |
|
57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults
|
Jul 06, 2025 |
|
56 - Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities
|
Jun 29, 2025 |
|
55 - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
|
Jun 22, 2025 |
|
54 - Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
|
Jun 02, 2025 |
|
53 - Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
|
May 02, 2025 |
|
52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
|
Apr 29, 2025 |
|
51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
|
Apr 13, 2025 |
|
50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
|
Apr 07, 2025 |
|
49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
|
Mar 18, 2025 |
|
48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
|
Mar 16, 2025 |
|
47 - Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
|
Mar 11, 2025 |
|
46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
|
Dec 29, 2024 |
|
45 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|
Dec 26, 2024 |
|
44 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML
|
Dec 23, 2024 |
|
43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
|
Nov 27, 2024 |
|
42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)
|
Nov 23, 2024 |
|
41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease
|
Nov 01, 2024 |
|
40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
|
Sep 27, 2024 |
|
39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
|
Sep 25, 2024 |
|
38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|
Sep 19, 2024 |
|
37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
|
Aug 24, 2024 |
|
36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
|
Aug 16, 2024 |
|
35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
|
Aug 05, 2024 |
|
34 - Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
|
Jul 27, 2024 |
|
33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
|
Jul 14, 2024 |
|
32 - The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial
|
Jul 12, 2024 |
|
31 - Remission induction vs immediate allogeneic HSCT for patients with relapsed or poor responsive AML (ASAP): a randomised, open-label, phase 3, non-inferiority trial
|
Jul 05, 2024 |
|
30 - Ibrutinib combined with immunochemotherapy with or without ASCT vs immunochemotherapy and ASCT in previously untreated patients with mantle cell lymphoma (TRIANGLE)
|
Jul 03, 2024 |
|
29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT
|
May 27, 2024 |
|
28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
|
Apr 24, 2024 |
|
27 - Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
|
Apr 14, 2024 |
|
26 - Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3
|
Apr 06, 2024 |
|
25 - PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors
|
Mar 28, 2024 |
|
24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
|
Mar 25, 2024 |
|
23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up
|
Mar 16, 2024 |
|
22 - Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention
|
Mar 03, 2024 |
|
21 - Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
|
Feb 29, 2024 |
|
20 - Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
|
Feb 17, 2024 |
|
19 - Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
|
Feb 04, 2024 |
|
18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|
Jan 29, 2024 |
|
17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
|
Jan 14, 2024 |
|
16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML
|
Dec 17, 2023 |
|
15 - Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation
|
Dec 03, 2023 |
|
14 - BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial
|
Nov 26, 2023 |
|
13 - R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
|
Nov 19, 2023 |
|
12 - PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
|
Nov 13, 2023 |
|
11 - Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER)
|
Oct 22, 2023 |
|
10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|
Oct 08, 2023 |
|
09 - Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis
|
Oct 02, 2023 |
|
08 - Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
|
Sep 24, 2023 |
|
07 - Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients
|
Aug 28, 2023 |
|
06 - Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
|
Aug 19, 2023 |
|
05 - Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD AML: long-term follow-up of an open-label, multicentre, randomised, phase 3
|
Aug 12, 2023 |
|
04 - Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3
|
Aug 05, 2023 |
|
03 - Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
|
Jul 29, 2023 |
|
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
|
Jul 21, 2023 |
|
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
|
Jul 16, 2023 |